A multicenter, randomized, controlled, prospective, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy

Administered By

Awarded By

Contributors

Start/End

  • April 22, 2020 - April 30, 2025